Adipose tissue dysfunction, inflammation, and insulin resistance: alternative pathways to cardiac remodelling in schizophrenia. A multimodal, case-control study.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
06 12 2021
06 12 2021
Historique:
received:
04
11
2021
accepted:
23
11
2021
revised:
17
11
2021
entrez:
7
12
2021
pubmed:
8
12
2021
medline:
1
2
2022
Statut:
epublish
Résumé
Cardiovascular diseases are the leading cause of death in schizophrenia. Patients with schizophrenia show evidence of concentric cardiac remodelling (CCR), defined as an increase in left-ventricular mass over end-diastolic volumes. CCR is a predictor of cardiac disease, but the molecular pathways leading to this in schizophrenia are unknown. We aimed to explore the relevance of hypertensive and non-hypertensive pathways to CCR and their potential molecular underpinnings in schizophrenia. In this multimodal case-control study, we collected cardiac and whole-body fat magnetic resonance imaging (MRI), clinical measures, and blood levels of several cardiometabolic biomarkers known to potentially cause CCR from individuals with schizophrenia, alongside healthy controls (HCs) matched for age, sex, ethnicity, and body surface area. Of the 50 participants, 34 (68%) were male. Participants with schizophrenia showed increases in cardiac concentricity (d = 0.71, 95% CI: 0.12, 1.30; p = 0.01), indicative of CCR, but showed no differences in overall content or regional distribution of adipose tissue compared to HCs. Despite the cardiac changes, participants with schizophrenia did not demonstrate activation of the hypertensive CCR pathway; however, they showed evidence of adipose dysfunction: adiponectin was reduced (d = -0.69, 95% CI: -1.28, -0.10; p = 0.02), with evidence of activation of downstream pathways, including hypertriglyceridemia, elevated C-reactive protein, fasting glucose, and alkaline phosphatase. In conclusion, people with schizophrenia showed adipose tissue dysfunction compared to body mass-matched HCs. The presence of non-hypertensive CCR and a dysmetabolic phenotype may contribute to excess cardiovascular risk in schizophrenia. If our results are confirmed, acting on this pathway could reduce cardiovascular risk and resultant life-years lost in people with schizophrenia.
Identifiants
pubmed: 34873143
doi: 10.1038/s41398-021-01741-9
pii: 10.1038/s41398-021-01741-9
pmc: PMC8648771
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
614Subventions
Organisme : Medical Research Council
ID : MC_U120085815
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_1102/19
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_1605/13
Pays : United Kingdom
Organisme : British Heart Foundation
ID : NH/17/1/32725
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
McCutcheon RA, Marques TR, Howes OD. Schizophrenia—an overview. JAMA Psychiatry. 2020;77:201–10.
pubmed: 31664453
doi: 10.1001/jamapsychiatry.2019.3360
Harris C, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.
pubmed: 9850203
doi: 10.1192/bjp.173.1.11
Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin psychiatry. 2012;25:83–8.
pubmed: 22249081
doi: 10.1097/YCO.0b013e32835035ca
Plana-Ripoll O, Pedersen CB, Agerbo E, Holtz Y, Erlangsen A, Canudas-Romo V, et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet. 2019;394:1827–35.
pubmed: 31668728
doi: 10.1016/S0140-6736(19)32316-5
Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6:675–712.
pubmed: 31324560
doi: 10.1016/S2215-0366(19)30132-4
De Hert M, Detraux J, Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci. 2018;20:31.
pubmed: 29946209
pmcid: 6016051
doi: 10.31887/DCNS.2018.20.1/mdehert
Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res. 2011;131:101–4.
pubmed: 21741216
doi: 10.1016/j.schres.2011.06.008
Parks J, Svendsen D, Singer P, Foti ME, Mauer B. Morbidity and mortality in people with serious mental illness. Alexandria, VA: National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council; 2006.
Osimo EF, Brugger SP, de Marvao A, Pillinger T, Whitehurst T, Statton B, et al. Cardiac structure and function in schizophrenia: a cardiac MR imaging study. Br J Psychiatry. 2020;217:450–7.
pubmed: 31915079
pmcid: 7511899
doi: 10.1192/bjp.2019.268
Pillinger T, Osimo EF, de Marvao A, Berry MA, Whitehurst T, Statton B, et al. Cardiac structure and function in patients with schizophrenia taking antipsychotic drugs: an MRI study. Transl Psychiatry. 2019;9:163.
pubmed: 31175270
pmcid: 6555792
doi: 10.1038/s41398-019-0502-x
Tsao CW, Gona PN, Salton CJ, Chuang ML, Levy D, Manning WJ, et al. Left ventricular structure and risk of cardiovascular events: a Framingham Heart Study Cardiac Magnetic Resonance Study. J Am Heart Assoc. 2015;4:e002188.
pubmed: 26374295
pmcid: 4599505
doi: 10.1161/JAHA.115.002188
Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896–908.
pubmed: 23462786
doi: 10.1001/jama.2013.1363
Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018;15:387–407.
pubmed: 29674714
doi: 10.1038/s41569-018-0007-y
Sapra M, Lawson D, Iranmanesh A, Varma A. Adiposity-independent hypoadiponectinemia as a potential marker of insulin resistance and inflammation in schizophrenia patients treated with second generation antipsychotics. Schizophr Res. 2016;174:132–6.
pubmed: 27211515
doi: 10.1016/j.schres.2016.04.051
Klöting N, Blüher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord. 2014;15:277–87.
pubmed: 25344447
doi: 10.1007/s11154-014-9301-0
Yudkin JS, Stehouwer C, Emeis J, Coppack S. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972–8.
pubmed: 10195925
doi: 10.1161/01.ATV.19.4.972
Bartoli F, Lax A, Crocamo C, Clerici M, Carrà G. Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis. Psychoneuroendocrinology. 2015;56:179–89.
pubmed: 25827962
doi: 10.1016/j.psyneuen.2015.03.012
Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol. 2008;121:326–30.
pubmed: 18061654
doi: 10.1016/j.jaci.2007.10.018
Mojiminiyi O, Abdella N, Al Arouj M, Nakhi AB. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int J Obes. 2007;31:213–20.
doi: 10.1038/sj.ijo.0803355
Christou G, Kiortsis D. Adiponectin and lipoprotein metabolism. Obes Rev. 2013;14:939–49.
pubmed: 23957239
doi: 10.1111/obr.12064
Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab. 2003;88:3236–40.
pubmed: 12843170
doi: 10.1210/jc.2002-021883
Ikejima K, Lang T, Yamashina S, Enomoto N, Takei Y, Sato N. Role of leptin in pathogenesis of NASH. In: Okita K, editor. NASH and nutritional therapy. Tokyo: Springer; 2005. pp. 44–9.
Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology. 2016;150:1769–77.
pubmed: 26928243
doi: 10.1053/j.gastro.2016.02.066
Morlán-Coarasa MJ, Arias-Loste MT, de la Foz VO-G, Martínez-García O, Alonso-Martín C, Crespo J, et al. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology. 2016;233:3947–52.
pubmed: 27620899
doi: 10.1007/s00213-016-4422-7
Fang L, Ellims AH, Beale AL, Taylor AJ, Murphy A, Dart AM. Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Am J Transl Res. 2017;9:5063.
pubmed: 29218105
pmcid: 5714791
Alpert MA, Karthikeyan K, Abdullah O, Ghadban R. Obesity and cardiac remodeling in adults: mechanisms and clinical implications. Prog Cardiovasc Dis. 2018;61:114–23.
pubmed: 29990533
doi: 10.1016/j.pcad.2018.07.012
VanWagner LB, Wilcox JE, Colangelo LA, Lloyd‐Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population‐based study. Hepatology. 2015;62:773–83.
pubmed: 25914296
doi: 10.1002/hep.27869
Archer CR, Robinson EL, Drawnel FM, Roderick HL. Endothelin-1 promotes hypertrophic remodelling of cardiac myocytes by activating sustained signalling and transcription downstream of endothelin type A receptors. Cell Signal. 2017;36:240–54.
pubmed: 28412414
pmcid: 5486433
doi: 10.1016/j.cellsig.2017.04.010
American College of Cardiology Foundation Task Force on Expert Consensus Documents, Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010;55:2614–62.
doi: 10.1016/j.jacc.2009.11.011
Osimo EF, Brugger SP, Thomas EL, Howes OD. Body fat volumes and distribution in chronic schizophrenia compared to healthy controls; a cross-sectional MR study. medRxiv:2021.2009.2020.21263820 [Preprint]. 2021 [cited 2021 Sep 22]: [11 p.]. Available from: https://doi.org/10.1101/2021.09.20.21263820 .
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.
pubmed: 3616518
doi: 10.1093/schbul/13.2.261
Matthews DR, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
pubmed: 3899825
doi: 10.1007/BF00280883
Torchiano M. Effsize - a package for efficient effect size computation. zenodo. 2016. https://zenodo.org/record/1480624#.YaNWyaJ5pPY .
Chen VC-H, Chen C-H, Chiu Y-H, Lin T-Y, Li F-C, Lu M-L. Leptin/adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia. Psychoneuroendocrinology. 2018;92:34–40.
pubmed: 29625373
doi: 10.1016/j.psyneuen.2018.03.021
Yan J, Hou C, Liang Y. The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease. Neuropsych Dis Treat. 2017;13:1493.
doi: 10.2147/NDT.S137183
Park SK, Ryoo J-H, Kang JG, Jung JY. Smoking status, intensity of smoking, and their relation to left ventricular hypertrophy in working aged Korean men. Nicotine Tob Res. 2021;23:1176–82.
pubmed: 33537724
doi: 10.1093/ntr/ntab020
Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975–81.
pubmed: 15502375
doi: 10.1253/circj.68.975
Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res. 2016;118:1786–807.
pubmed: 27230642
pmcid: 4887147
doi: 10.1161/CIRCRESAHA.115.306885
Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473–6.
pubmed: 10604883
doi: 10.1161/01.CIR.100.25.2473
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–7.
pubmed: 15082700
doi: 10.1001/jama.291.14.1730
Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable? Eur Heart J. 2000;21:1387–96.
pubmed: 10952828
doi: 10.1053/euhj.2000.2011
Forde C, Murphy N, Meaney J, Kennedy P, Boyle G. Comparison of bioelectrical impedance analysis and magnetic resonance imaging for the quantification of fat mass. Int J Physiatry. 2015;1:003
doi: 10.23937/2572-4215.1510003
Chaudry O, Grimm A, Friedberger A, Kemmler W, Uder M, Jakob F, et al. Magnetic resonance imaging and bioelectrical impedance analysis to assess visceral and abdominal adipose tissue. Obesity. 2020;28:277–83.
pubmed: 31898402
doi: 10.1002/oby.22712
Wong ND, Gardin JM, Kurosaki T, Anton-Culver H, Sidney S, Roseman J, et al. Echocardiographic left ventricular systolic function and volumes in young adults: distribution and factors influencing variability. Am Heart J. 1995;129:571–7.
pubmed: 7872189
doi: 10.1016/0002-8703(95)90287-2
Aijaz B, Ammar KA, Lopez-Jimenez F, Redfield MM, Jacobsen SJ, Rodeheffer RJ. Abnormal cardiac structure and function in the metabolic syndrome: a population-based study. Mayo Clin Proc. 2008;83:1350–7.
pubmed: 19046554
doi: 10.4065/83.12.1350
Cheitlin MD. Cardiovascular physiology—changes with aging. Am J Geriatr Cardiol. 2003;12:9–13.
pubmed: 12502909
doi: 10.1111/j.1076-7460.2003.01751.x
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77.
pubmed: 31860457
pmcid: 7029416
doi: 10.1016/S2215-0366(19)30416-X
Lu M-L, Wang T-N, Lin T-Y, Shao W-C, Chang S-H, Chou J-Y, et al. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog Neuropsychopharmacol Biol Psychiatry. 2015;58:47–50.
pubmed: 25496829
doi: 10.1016/j.pnpbp.2014.12.001
Pillinger T, Osimo EF, Brugger S, Mondelli V, McCutcheon RA, Howes OD. A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis. Schizophr Bull. 2019;45:1120–33.
pubmed: 30407606
doi: 10.1093/schbul/sby160
Pillinger T, Beck K, Stubbs B, Howes OD. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry. 2017;211:339–49.
pubmed: 28982658
pmcid: 5709673
doi: 10.1192/bjp.bp.117.200907
Bai YM, Chen J-Y, Yang W-S, Chi Y-C, Liou Y-J, Lin C-C, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry. 2007;68:1834–9.
pubmed: 18162013
doi: 10.4088/JCP.v68n1202
Bai YM, Chen TT, Yang W-S, Chi Y-C, Lin C-C, Liou Y-J, et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res. 2009;111:1–8.
pubmed: 19409756
doi: 10.1016/j.schres.2009.03.014
Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, Turkbey EB, Williams R, et al. Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson. 2015;17:29.
pubmed: 25928314
pmcid: 4403942
doi: 10.1186/s12968-015-0111-7
Corden B, Keenan NG, de Marvao AS, Dawes TJ, DeCesare A, Diamond T, et al. Body fat is associated with reduced aortic stiffness until middle age. Hypertension. 2013;61:1322–7.
pubmed: 23608657
doi: 10.1161/HYPERTENSIONAHA.113.01177